Dag Aarsland (United Kingdom)
King's College London Institute of Pscyhiatry, Psychology and NeuroscienceAuthor Of 2 Presentations
MANAGEMENT OF BEHAVIORAL SYMPTOMS IN DEMENTIA
- Dag Aarsland (United Kingdom)
NEW ADVANCES IN LEWY BODY DISEASE
- Dag Aarsland (United Kingdom)
Abstract
Abstract Body
Lewy body disease comprises a group of disorders were aggregation of alpha-synuclein leads to neurodegeneration in various brain regions. The most common are Parkinson’s disease and dementia with Lewybodies (DLB). This presentation will outline the key clinical and pathological features of DLB, and present new advances in epidemiology and pathology. New findings and research criteria of prodromal DLB will be discussed, including the interface with Parkinson’s disease.
New findings related to diagnostic and prognostic biomarkers will be presented, including imaging, EEG, blood and CSF based markers, including the potential role of the ne real-time quaking-induced conversion (RT-QUIC) technique, in CSF, blood and other tissues.
The recently proposed DIAMOND-Lewy management guidelines will be presented and discussed, as well as recent pharmacological and non-pharmacological trials. Ongoing and planned trials will be reviewed. There is a huge need for increased global awareness to increase detection, diagnosis and management of DLB, and a recent global initiative to address this need will be presented.
Presenter of 2 Presentations
MANAGEMENT OF BEHAVIORAL SYMPTOMS IN DEMENTIA
- Dag Aarsland (United Kingdom)
NEW ADVANCES IN LEWY BODY DISEASE
- Dag Aarsland (United Kingdom)
Abstract
Abstract Body
Lewy body disease comprises a group of disorders were aggregation of alpha-synuclein leads to neurodegeneration in various brain regions. The most common are Parkinson’s disease and dementia with Lewybodies (DLB). This presentation will outline the key clinical and pathological features of DLB, and present new advances in epidemiology and pathology. New findings and research criteria of prodromal DLB will be discussed, including the interface with Parkinson’s disease.
New findings related to diagnostic and prognostic biomarkers will be presented, including imaging, EEG, blood and CSF based markers, including the potential role of the ne real-time quaking-induced conversion (RT-QUIC) technique, in CSF, blood and other tissues.
The recently proposed DIAMOND-Lewy management guidelines will be presented and discussed, as well as recent pharmacological and non-pharmacological trials. Ongoing and planned trials will be reviewed. There is a huge need for increased global awareness to increase detection, diagnosis and management of DLB, and a recent global initiative to address this need will be presented.
Moderator of 2 Sessions
- Dag Aarsland (United Kingdom)
- Dag Aarsland (United Kingdom)